|
Market Closed -
Börse Stuttgart
15:56:38 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 9.300 EUR | +0.54% |
|
-2.12% | +6.32% |
| 10-01 | SpyGlass Pharma Acquires Advanced Vision Science for $13 Million | MT |
| 09-30 | SpyGlass Pharma, Inc. acquired Advanced Vision Science, Inc. from Santen Pharmaceutical Co., Ltd. for $13 million. | CI |
Company Valuation: Santen Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 490,898 | 424,342 | 559,190 | 484,047 | 574,345 | 540,724 | - | - |
| Change | - | -13.56% | 31.78% | -13.44% | 18.65% | -5.85% | - | - |
| Enterprise Value (EV) 1 | 406,591 | 366,439 | 464,338 | 425,279 | 552,218 | 493,983 | 464,836 | 422,860 |
| Change | - | -9.88% | 26.72% | -8.41% | 29.85% | -10.55% | -5.9% | -9.03% |
| P/E | 18x | -29.3x | 21.2x | 13.6x | 15.7x | 14x | 12.4x | 11.7x |
| PBR | 1.45x | 1.44x | 1.82x | 1.69x | 1.93x | 1.7x | 1.58x | 1.46x |
| PEG | - | 0x | -0x | 0.3x | 1.62x | 2.47x | 1x | 1.81x |
| Capitalization / Revenue | 1.84x | 1.52x | 1.85x | 1.61x | 1.97x | 1.78x | 1.73x | 1.67x |
| EV / Revenue | 1.53x | 1.31x | 1.54x | 1.42x | 1.89x | 1.62x | 1.49x | 1.3x |
| EV / EBITDA | 7.68x | 25.9x | 8.19x | 6.56x | 8.35x | 7.18x | 6.43x | 5.48x |
| EV / EBIT | 11.3x | -119x | 12x | 9.07x | 11.6x | 9.8x | 8.43x | 7.02x |
| EV / FCF | 37.4x | 35.3x | 6.98x | 8.07x | 18.1x | 15.6x | 11.6x | 9.19x |
| FCF Yield | 2.67% | 2.83% | 14.3% | 12.4% | 5.53% | 6.42% | 8.64% | 10.9% |
| Dividend per Share 2 | 32 | 32 | 33 | 36 | 38 | 41.62 | 46.78 | 51.75 |
| Rate of return | 2.61% | 2.83% | 2.15% | 2.54% | 2.13% | 2.47% | 2.78% | 3.07% |
| EPS 2 | 68.07 | -38.6 | 72.59 | 104 | 114 | 120.5 | 135.5 | 144.3 |
| Distribution rate | 47% | -82.9% | 45.5% | 34.6% | 33.3% | 34.5% | 34.5% | 35.9% |
| Net sales 1 | 266,257 | 279,037 | 301,965 | 300,004 | 291,624 | 304,042 | 312,697 | 324,581 |
| EBITDA 1 | 52,941 | 14,159 | 56,719 | 64,828 | 66,155 | 68,761 | 72,283 | 77,100 |
| EBIT 1 | 35,886 | -3,090 | 38,541 | 46,880 | 47,797 | 50,399 | 55,133 | 60,220 |
| Net income 1 | 27,218 | -14,948 | 26,642 | 36,256 | 37,369 | 38,219 | 40,848 | 44,690 |
| Net Debt 1 | -84,307 | -57,903 | -94,852 | -58,768 | -22,127 | -46,741 | -75,888 | -117,864 |
| Reference price 2 | 1,227.00 | 1,130.00 | 1,536.50 | 1,418.00 | 1,785.50 | 1,683.50 | 1,683.50 | 1,683.50 |
| Nbr of stocks (in thousands) | 400,080 | 375,524 | 363,938 | 341,359 | 321,672 | 321,190 | - | - |
| Announcement Date | 5/10/22 | 5/11/23 | 5/9/24 | 5/13/25 | 5/12/26 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.46x | 11.79x | 23.8x | 0.61% | 1,019B | |
| 28.13x | 6.24x | 17.86x | 2.11% | 610B | |
| 33.64x | 7.86x | 16.24x | 2.61% | 470B | |
| 101.52x | 5.7x | 24.22x | 2.45% | 344B | |
| 18.95x | 4.61x | 11.45x | 2.87% | 336B | |
| 19.74x | 5.16x | 12.75x | 3.1% | 266B | |
| 19.84x | 4.13x | 11.77x | 2.15% | 241B | |
| 25.45x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.74x | 6.39x | 24.95x | 2.28% | 179B | |
| Average | 26.22x | 6.50x | 17.21x | 2.3% | 409.2B | |
| Weighted average by Cap. | 31.25x | 7.60x | 18.53x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 4536 Stock
- SZD Stock
- Valuation Santen Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
